文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

肌肉LIM蛋白力感知介导家族性肥厚型心肌病肌节生物力学信号

Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2022-04-06

该研究利用患者iPSC来源心肌细胞构建工程化心脏组织,结合计算建模与基因编辑,揭示肌节突变增强肌动球蛋白横桥形成和力生成,破坏Z盘MLP牵张感知复合体,激活钙调磷酸酶-NFAT信号促肥厚;MLP-W4R变异可加重表型,基因或药物干预可减轻Z盘应力并预防肥厚。

要点

  • 肌节突变通过增强横桥形成和力生成,破坏Z盘MLP机械感知复合体。
  • MLP减少解除钙调磷酸酶-NFAT信号抑制,促进心肌肥厚。
  • MLP-W4R是加重HCM表型的重要修饰因子,但单独可能不致病变。

核心结论

  • 研究发现肌节力产生失调通过Z盘MLP机械感知复合体触发病理信号和肥厚反应的新机制。
  • MLP-W4R变异可加重HCM表型,但单独可能不是致病突变。
  • 减轻横桥形成可预防肌节突变相关肥厚,为机制导向治疗提供基础。

研究设计与样本

  • 基于一例严重HCM患者及第二个肌节机械感知蛋白遗传改变的发现。
  • 利用患者特异性iPSC来源心肌细胞,接种于激光切割且具原生心肌纤维排列的支架构建工程化心脏组织。
  • 结合肌肉收缩计算建模,并通过基因编辑和药物干预挽救疾病表型。
  • 在5个携带不同肌节突变的家族中验证该机械转导通路。

主要发现

  • 心肌肌球蛋白重链(MYH7)肌节突变增强肌动球蛋白横桥形成,导致力生成增加。
  • 力增加伴慢速抽搐松弛,使Z盘MLP牵张感知复合体不稳定。
  • 肌节MLP水平降低解除钙调磷酸酶-NFAT信号抑制,促进心肌肥厚。
  • MLP-W4R变异加重HCM表型表达,但单独可能不致病变。

临床怎么用

  • MLP-W4R可作为HCM表型加重的遗传修饰因子进行评估。
  • 针对增强横桥形成的基因或药物干预可能减轻Z盘应力并预防肥厚。
  • 稳定Z盘MLP机械感知复合体是HCM机制导向治疗的新方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Familial hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disease and is typically caused by mutations in genes encoding sarcomeric proteins that regulate cardiac contractility. HCM manifestations include left ventricular hypertrophy and heart failure, arrythmias, and sudden cardiac death. How dysregulated sarcomeric force production is sensed and leads to pathological remodeling remains poorly understood in HCM, thereby inhibiting the efficient development of new therapeutics. METHODS: Our discovery was based on insights from a severe phenotype of an individual with HCM and a second genetic alteration in a sarcomeric mechanosensing protein. We derived cardiomyocytes from patient-specific induced pluripotent stem cells and developed robust engineered heart tissues by seeding induced pluripotent stem cell-derived cardiomyocytes into a laser-cut scaffold possessing native cardiac fiber alignment to study human cardiac mechanobiology at both the cellular and tissue levels. Coupled with computational modeling for muscle contraction and rescue of disease phenotype by gene editing and pharmacological interventions, we have identified a new mechanotransduction pathway in HCM, shown to be essential in modulating the phenotypic expression of HCM in 5 families bearing distinct sarcomeric mutations. RESULTS: Enhanced actomyosin crossbridge formation caused by sarcomeric mutations in cardiac myosin heavy chain (MYH7) led to increased force generation, which, when coupled with slower twitch relaxation, destabilized the MLP (muscle LIM protein) stretch-sensing complex at the Z-disc. Subsequent reduction in the sarcomeric muscle LIM protein level caused disinhibition of calcineurin-nuclear factor of activated T-cells signaling, which promoted cardiac hypertrophy. We demonstrate that the common muscle LIM protein-W4R variant is an important modifier, exacerbating the phenotypic expression of HCM, but alone may not be a disease-causing mutation. By mitigating enhanced actomyosin crossbridge formation through either genetic or pharmacological means, we alleviated stress at the Z-disc, preventing the development of hypertrophy associated with sarcomeric mutations. CONCLUSIONS: Our studies have uncovered a novel biomechanical mechanism through which dysregulated sarcomeric force production is sensed and leads to pathological signaling, remodeling, and hypertrophic responses. Together, these establish the foundation for developing innovative mechanism-based treatments for HCM that stabilize the Z-disc MLP-mechanosensory complex.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Riaz M, Park J, Sewanan LR, et al. Muscle LIM Protein Force-Sensing Mediates Sarcomeric Biomechanical Signaling in Human Familial Hypertrophic Cardiomyopathy. Circulation. 2022. PMID: 35384713. doi:10.1161/CIRCULATIONAHA.121.056265

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。